7-(三氟甲基)-1,2,3,4-四氢异喹啉 | 199678-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 7-(三氟甲基)-1,2,3,4-四氢异喹啉
• 中文别名: 1,2,3,4-四氢-7-三氟甲基异喹啉
• 英文名称: 7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline
• CAS: 199678-32-5
• 化学式: C₁₀H₁₀F₃N
• mdl: MFCD08059296
• 分子量: 201.191
• InChiKey: NGQHLYGRTFVUEM-UHFFFAOYSA-N

物化性质

• 沸点：
  228.9±35.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933499090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-(Trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-(Trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline
CAS number: 199678-32-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10F3N
Molecular weight: 201.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-(三氟甲基)-1,2,3,4-四氢异喹啉 在 盐酸 、 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 37.0h， 生成 ((1S,3R)-3-amino-1-isopropylcyclopentyl)(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone
  参考文献：
  名称：

  Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity

  摘要：

  公式(I)的化合物是化学趋化因子受体活性调节剂，对预防或治疗某些炎症和免疫调节性疾病和疾病、过敏性疾病、包括过敏性鼻炎、皮炎、结膜炎和哮喘等特应性疾病，以及风湿性关节炎和动脉粥样硬化等自身免疫病理学，以及包含这些化合物的药物组合物，以及这些化合物和组合物在涉及化学趋化因子受体的疾病的预防或治疗中的用途。

  公开号：

  US20070117797A1
• 作为产物：
  描述：

  2-(4-三氟甲基苯基)乙胺 在 硫酸 、 potassium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 生成 7-(三氟甲基)-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  7-（三氟甲基）异喹啉-5-胺的合成方法

  摘要：

  本发明公开了一种7‑（三氟甲基）异喹啉‑5‑胺的合成方法，以对三氟甲基苯乙胺原料与TFAA经过氨基保护，关环，水解，溴代，脱溴插烯，脱氢芳构化得到7‑三氟甲基异喹啉，和NBS进行5位溴代得到5‑溴‑7‑三氟甲基异喹啉，与NH2Boc进行钯催化偶联和水解得到7‑（三氟甲基）异喹啉‑5‑胺。本发明为7‑（三氟甲基）异喹啉‑5‑胺的合成提供了新的合成路线，本发明以对三氟甲基苯乙胺为原料，合成路线简洁，工艺选择合理，原料成本低，原料简单易得，操作和后处理方便，总收率高，不使用剧毒试剂，易于放大，可进行大规模生产。

  公开号：

  CN112457245B

文献信息

• [EN] FUSED CYCLOPENTYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES CYCLOPENTYLIQUES FUSIONNÉS DE CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2013152269A1

  公开（公告）日：2013-10-10

  The present invention comprises compounds of Formula (I). Formula (I) wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了式（I）的化合物。式（I）中：R0、R1、R2、R3、R4、R5和A的定义如规范中所述。该发明还涵盖了一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是2型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators
  申请人：Ares Trading SA

  公开号：EP2508526A1

  公开（公告）日：2012-10-10

  The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。
• Pharmaceutical compositions and methods of inhibiting phenylethanolamine
  申请人：SmithKline Corporation

  公开号：US03988339A1

  公开（公告）日：1976-10-26

  Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using 7 and/or 8 substituted 1,2,3,4-tetrahydroisoquinoline compounds.

  制药组合物和使用7和/或8取代的1,2,3,4-四氢异喹啉化合物抑制苯乙醇胺N-甲基转移酶的方法。
• [EN] HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLE À UTILISER EN TANT QU'INHIBITEURS DE SÉPIAPTÉRINE RÉDUCTASE
  申请人：QUARTET MEDICINE INC

  公开号：WO2017059191A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

  式(I)或(I')的色氨酰还原酶抑制剂，其中取代基如权利要求中所定义，以及这些色氨酰还原酶抑制剂在镇痛、治疗急慢性疼痛、抗炎和免疫细胞调节中的用途被公开。
• [EN] AMINO HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] COMPOSES AMINO HETEROCYCLIQUES MODULATEURS DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINES
  申请人：MERCK & CO INC

  公开号：WO2005080371A1

  公开（公告）日：2005-09-01

  Compounds of Formula I and Formula II: (wherein n, R 1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33 R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

  公式I和公式II的化合物（其中n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R15、R16、R17、R18、R19、R24、R25、R26、R27、R28、R29、R30、R33、R34、R35、R36、R37、R38、A、j、k、m、n、X、Y和Z按本说明书中定义）：这些化合物是趋化因子受体活性的调节剂，可用于预防或治疗某些炎症和免疫调节紊乱和疾病、过敏性疾病、变应性条件包括过敏性鼻炎、皮炎、结膜炎和哮喘，以及自身免疫病理学如类风湿性关节炎和动脉粥样硬化。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。